![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novo Nordisk (PK) | USOTC:NONOF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.358 | -0.27% | 131.142 | 127.55 | 135.67 | 137.34 | 128.64 | 137.34 | 382,916 | 21:00:01 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 5, 2021
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [X] | Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] | No [X] |
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021
Bagsværd, Denmark, 5 November 2021 — This document discloses the
data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons
in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find in the attached document a statement of such trading in shares issued by Novo Nordisk.
PublicationDefinitions
and background information:
Publication shall take place no later than three working days after the trading by board members, executives or their associated persons. Publication is only required when the total amount of transactions of a specific board member/executive or his/her associated persons in any one calendar year has reached EUR 20,000 (calculated individually).
Who
are board members, executives and associated persons?
Board members and executives
are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk
A/S. Associated persons are defined as the following persons associated to a board member/executive:
1) spouse or cohabitant, 2) children under the age of 18 years, 3) Other relatives defined
as brothers, sisters, parents, grandparents, children, grandchildren, cousins etc. who have
shared the same household with a board member or executive for a period of at least one year
on the date of the given transaction and 4) any legal persons, trust, or partnership, the
managerial responsibilities of which are discharged by a board member/executive or by a person
referred to in items 1)-3) above, or which is directly or indirectly controlled by such a
person, or which is set up for the benefit of such a person, or the economic interests of
which are substantially equivalent to those of such a person.
What
is trading/transaction?
Trading is any kind of transaction, including shares and
share related securities purchased or otherwise acquired, sold or otherwise disposed, gifts,
mortgages, heritage and grants, allotments and exercise of options.
What
is financial instrument and ID code?
Financial instrument includes shares listed
on the Nasdaq Copenhagen and ADRs listed on New York Stock Exchange, except for ADRs held
in 401(k) retirement plan by US-based employees. The ID code is the code (ISIN DK0060534915)
of the Novo Nordisk share on the Nasdaq Copenhagen or the code (NVO) on New York Stock Exchange.
What
is date and place of transaction?
Date of transaction is the actual transaction
date. The place of transaction is the actual place of transaction, i.e. Nasdaq Copenhagen
or New York Stock Exchange.
What is the volume
and price of transaction and aggregated information?
The volume of transaction is
the number of shares (of DKK 0.20 nominal value) or other financial instruments traded. In
case of a single transaction the price is the price of that single transaction. In case of
multiple transactions, when the transactions relate to the same financial instrument, are
of the same nature, are executed on the same day and are executed on the same place, the
volume must be aggregated. The price of the aggregated transactions is the weighted average
price.
The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction value in DKK in case of ADRs listed on New York Stock Exchange.
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet:
24 25 67 90 |
Company announcement No 70 / 2021 |
Page 2 of 2
About Novo Nordisk A/S
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity
and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working
to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170
countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
Further information
Media: | ||
Mette Kruse Danielsen | +45 3079 3883 | mkd@novonordisk.com |
Michael Bachner (US) | +1 609 664 7308 | mzyb@novonordisk.com |
Investors: | ||
Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
David Heiberg Landsted | +45 3077 6915 | dhel@novonordisk.com |
Mark Joseph Root | +45 3079 4211 | mjhr@novonordisk.com |
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet:
24 25 67 90 |
Company announcement No 70 / 2021 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: November 5, 2021 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen Chief Executive Officer |
1 Year Novo Nordisk (PK) Chart |
1 Month Novo Nordisk (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions